Multiple Myeloma Research Foundation - MMRF's The Right Track Program | High Impact Topic (HIT)
Patient Symposium - MCRT Webcast Myeloma Crowd Round Table, 10/16/2021 - St. Louis, Missouri
The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of RRMM treated with IRd
Siteman Cancer Center: Learn about cancer clinical trials and the benefits they offer patients
NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
NCT04754100: Phase 1 - AGENT-797 in Participants With Relapsed/Refractory Multiple Myeloma
Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of RRMM
NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM
Multiple Myeloma Research Foundation - MMRF - Immunotherapy
FDA Approved for RRMM: Sarclisa (isatuximab-irfc) + Kyprolis (Carfilzomib) and Dexamethasone (IKd)
NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Multiple Myeloma, Lymphoma, Leukemia
NCT04998786: Phase 2: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide & Dex RRMM
NCCN Animation for Patients: What is Multiple Myeloma?
NCT05053607: Real World Insights During Treatment for Relapsed/Refractory Myeloma With Isatuximab
NCT05136807: Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
NCT04772989: Phase 1: A Study to Evaluate AB308 in Combination With AB122 in Participants With MM
RRMM:Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Pomalidomide (Pomalyst) & Dexamethasone
NCT04702425: phase 1: VOB560-MIK665 Combination First in Human Trial in Patients With Hem. Malig.
NCT05113342: Phase 1/2: Descartes-25 in Relapsed/Refractory Multiple Myeloma